-
(
GalettaDRossiAPiscontiSet al
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets
2012; 16(Suppl. 2): SS45–SS54.)
GalettaDRossiAPiscontiSet al
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets
2012; 16(Suppl. 2): SS45–SS54.
GalettaDRossiAPiscontiSet al
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets
2012; 16(Suppl. 2): SS45–SS54.,
GalettaDRossiAPiscontiSet al
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Ther Targets
2012; 16(Suppl. 2): SS45–SS54.
-
(
TakeuchiKChoiYLTogashiYet al
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancer. Clin Cancer Res
2009; 15: 3143–3149.19383809)
TakeuchiKChoiYLTogashiYet al
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancer. Clin Cancer Res
2009; 15: 3143–3149.19383809
TakeuchiKChoiYLTogashiYet al
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancer. Clin Cancer Res
2009; 15: 3143–3149.19383809,
TakeuchiKChoiYLTogashiYet al
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancer. Clin Cancer Res
2009; 15: 3143–3149.19383809
-
(
MezquitaLBesseB.
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis
2016; 8: 2997–3002.28066567)
MezquitaLBesseB.
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis
2016; 8: 2997–3002.28066567
MezquitaLBesseB.
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis
2016; 8: 2997–3002.28066567,
MezquitaLBesseB.
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. J Thorac Dis
2016; 8: 2997–3002.28066567
-
T.
Uemura,
T.
Hida
(2017)
Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer.
Annals of translational medicine, 5 21
-
(
CasaluceFSgambatoASaccoPCet al
Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies. Curr Clin Pharmacol
2016; 11: 77–87.27138017)
CasaluceFSgambatoASaccoPCet al
Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies. Curr Clin Pharmacol
2016; 11: 77–87.27138017
CasaluceFSgambatoASaccoPCet al
Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies. Curr Clin Pharmacol
2016; 11: 77–87.27138017,
CasaluceFSgambatoASaccoPCet al
Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies. Curr Clin Pharmacol
2016; 11: 77–87.27138017
-
(
GainorJFDardaeiLYodaSet al
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discov
2016; 6: 1118–1133.27432227)
GainorJFDardaeiLYodaSet al
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discov
2016; 6: 1118–1133.27432227
GainorJFDardaeiLYodaSet al
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discov
2016; 6: 1118–1133.27432227,
GainorJFDardaeiLYodaSet al
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discov
2016; 6: 1118–1133.27432227
-
(2010)
The biology and treatment of EML4-ALK nonsmall cell lung cancer
-
(
ShawATYeapBYMino-KenudsonMet al
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol
2009; 27: 4247–4253.19667264)
ShawATYeapBYMino-KenudsonMet al
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol
2009; 27: 4247–4253.19667264
ShawATYeapBYMino-KenudsonMet al
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol
2009; 27: 4247–4253.19667264,
ShawATYeapBYMino-KenudsonMet al
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol
2009; 27: 4247–4253.19667264
-
Jessica
Lin,
Gregory
Riely,
A.
Shaw
(2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance.
Cancer discovery, 7 2
-
(2014)
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial T Vavalà and S Novello journals.sagepub.com/home/tam 11 metastases
-
(
KrisMJohnsonBEBerryLDet al
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA
2014; 311: 1998–2006.24846037)
KrisMJohnsonBEBerryLDet al
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA
2014; 311: 1998–2006.24846037
KrisMJohnsonBEBerryLDet al
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA
2014; 311: 1998–2006.24846037,
KrisMJohnsonBEBerryLDet al
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA
2014; 311: 1998–2006.24846037
-
(
RikovaKGuoAZengQet al
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell
2007; 131: 1190–1203.18083107)
RikovaKGuoAZengQet al
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell
2007; 131: 1190–1203.18083107
RikovaKGuoAZengQet al
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell
2007; 131: 1190–1203.18083107,
RikovaKGuoAZengQet al
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell
2007; 131: 1190–1203.18083107
-
A.
Shaw,
B.
Yeap,
M.
Mino‐Kenudson,
S.
Digumarthy,
D.
Costa,
R.
Heist,
B.
Solomon,
Hannah
Stubbs,
S.
Admane,
U.
McDermott,
J.
Settleman,
Susumu
Kobayashi,
E.
Mark,
S.
Rodig,
L.
Chirieac,
E.
Kwak,
T.
Lynch,
A.
Iafrate
(2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
-
Young
Kim,
T.
Hida,
H.
Nokihara,
M.
Kondo,
K.
Azuma,
T.
Seto,
Y.
Takiguchi,
M.
Nishio,
H.
Yoshioka,
F.
Imamura,
K.
Hotta,
Satoshi
Watanabe,
K.
Goto,
K.
Nakagawa,
T.
Mitsudomi,
N.
Yamamoto,
H.
Kuriki,
Ryoichi
Asabe,
Tomohiro
Tanaka,
T.
Tamura
(2017)
MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)
Journal of Thoracic Oncology, 12
-
(
SetoTKiuraKNishioMet al
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol
2013; 14: 590–598.23639470)
SetoTKiuraKNishioMet al
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol
2013; 14: 590–598.23639470
SetoTKiuraKNishioMet al
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol
2013; 14: 590–598.23639470,
SetoTKiuraKNishioMet al
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol
2013; 14: 590–598.23639470
-
(
GainorJFChiASLoganJet al
Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol
2016; 11: 256–260.26845119)
GainorJFChiASLoganJet al
Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol
2016; 11: 256–260.26845119
GainorJFChiASLoganJet al
Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol
2016; 11: 256–260.26845119,
GainorJFChiASLoganJet al
Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol
2016; 11: 256–260.26845119
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2017)
Cancer statistics, 2017
CA: A Cancer Journal for Clinicians, 67
-
two approvals for ALKpositive non-small cell lung cancer
-
alectinib hydrochloride capsule
-
I.
Muller,
A.
Langen,
R.
Honeywell,
E.
Giovannetti,
G.
Peters
(2016)
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
Expert Review of Anticancer Therapy, 16
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
L.
Hernández,
M.
Pinyol,
S.
Hernández,
S.
Beà,
K.
Pulford,
A.
Rosenwald,
L.
Lamant,
B.
Falini,
G.
Ott,
D.
Mason,
G.
Delsol,
E.
Campo
(1999)
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
Blood, 94 9
-
S.
Ou,
K.
Sommers,
Michele
Azada,
E.
Garon
(2015)
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
The oncologist, 20 2
-
(
UemuraTHidaT.
Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. Ann Transl Med
2017; 5: 433: 1–6.28164086)
UemuraTHidaT.
Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. Ann Transl Med
2017; 5: 433: 1–6.28164086
UemuraTHidaT.
Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. Ann Transl Med
2017; 5: 433: 1–6.28164086,
UemuraTHidaT.
Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. Ann Transl Med
2017; 5: 433: 1–6.28164086
-
G.
Hamilton,
Barbara
Rath,
O.
Burghuber
(2015)
Pharmacokinetics of crizotinib in NSCLC patients
Expert Opinion on Drug Metabolism & Toxicology, 11
-
(2010)
Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer
-
(
PetersSCamidgeDRShawATet al
Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med
2017; 377: 829–838.28586279)
PetersSCamidgeDRShawATet al
Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med
2017; 377: 829–838.28586279
PetersSCamidgeDRShawATet al
Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med
2017; 377: 829–838.28586279,
PetersSCamidgeDRShawATet al
Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med
2017; 377: 829–838.28586279
-
(
KodamaTHasegawaMTakanashiKet al
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol
2014; 74: 1023–1028.25205428)
KodamaTHasegawaMTakanashiKet al
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol
2014; 74: 1023–1028.25205428
KodamaTHasegawaMTakanashiKet al
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol
2014; 74: 1023–1028.25205428,
KodamaTHasegawaMTakanashiKet al
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol
2014; 74: 1023–1028.25205428
-
Takaaki
Sasaki,
S.
Rodig,
L.
Chirieac,
P.
Jänne
(2010)
The biology and treatment of EML4-ALK non-small cell lung cancer.
European journal of cancer, 46 10
-
(
NovelloSMazieresJOhI-Jet al
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol
2017; 28(Suppl. 5): v605-v649.)
NovelloSMazieresJOhI-Jet al
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol
2017; 28(Suppl. 5): v605-v649.
NovelloSMazieresJOhI-Jet al
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol
2017; 28(Suppl. 5): v605-v649.,
NovelloSMazieresJOhI-Jet al
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol
2017; 28(Suppl. 5): v605-v649.
-
(
HallbergBPalmerRH.
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer
2013; 13: 685–700.24060861)
HallbergBPalmerRH.
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer
2013; 13: 685–700.24060861
HallbergBPalmerRH.
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer
2013; 13: 685–700.24060861,
HallbergBPalmerRH.
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer
2013; 13: 685–700.24060861
-
(
OuSHISommersKRAzadaMCet al
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist
2015; 20: 224–226.25568147)
OuSHISommersKRAzadaMCet al
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist
2015; 20: 224–226.25568147
OuSHISommersKRAzadaMCet al
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist
2015; 20: 224–226.25568147,
OuSHISommersKRAzadaMCet al
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist
2015; 20: 224–226.25568147
-
M.
Kris,
B.
Johnson,
L.
Berry,
D.
Kwiatkowski,
A.
Iafrate,
I.
Wistuba,
M.
Varella-Garcia,
W.
Franklin,
S.
Aronson,
P.
Su,
Y.
Shyr,
D.
Camidge,
L.
Sequist,
B.
Glisson,
F.
Khuri,
E.
Garon,
W.
Pao,
C.
Rudin,
J.
Schiller,
E.
Haura,
M.
Socinski,
K.
Shirai,
Heidi
Chen,
G.
Giaccone,
M.
Ladanyi,
K.
Kugler,
J.
Minna,
P.
Bunn
(2014)
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
JAMA, 311 19
-
(
CamidgeDRGadgeelSOuSHet al
MA07.02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thoracic Oncol
2017; 12(Suppl.): S378.)
CamidgeDRGadgeelSOuSHet al
MA07.02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thoracic Oncol
2017; 12(Suppl.): S378.
CamidgeDRGadgeelSOuSHet al
MA07.02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thoracic Oncol
2017; 12(Suppl.): S378.,
CamidgeDRGadgeelSOuSHet al
MA07.02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer. J Thoracic Oncol
2017; 12(Suppl.): S378.
-
Sarah
Sabir,
S.
Yeoh,
G.
Jackson,
R.
Bayliss
(2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Cancers, 9
-
(
U.S. Food and Drug Administration. FDA D.I.S.C.O.: two approvals for ALK-positive non-small cell lung cancer, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm568436.htm (accessed 25 January 2018).)
U.S. Food and Drug Administration. FDA D.I.S.C.O.: two approvals for ALK-positive non-small cell lung cancer, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm568436.htm (accessed 25 January 2018).
U.S. Food and Drug Administration. FDA D.I.S.C.O.: two approvals for ALK-positive non-small cell lung cancer, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm568436.htm (accessed 25 January 2018).,
U.S. Food and Drug Administration. FDA D.I.S.C.O.: two approvals for ALK-positive non-small cell lung cancer, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm568436.htm (accessed 25 January 2018).
-
Yuki
Togashi,
M.
Soda,
S.
Sakata,
E.
Sugawara,
S.
Hatano,
R.
Asaka,
T.
Nakajima,
H.
Mano,
K.
Takeuchi
(2012)
KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
PLoS ONE, 7
-
(
GadgeelSMShawATGovindanRet al
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol
2016; 34: 4079–4085.27863201)
GadgeelSMShawATGovindanRet al
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol
2016; 34: 4079–4085.27863201
GadgeelSMShawATGovindanRet al
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol
2016; 34: 4079–4085.27863201,
GadgeelSMShawATGovindanRet al
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol
2016; 34: 4079–4085.27863201
-
(
GainorJFShermanCAWilloughbyKet al
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol
2015; 10: 232–236.25526238)
GainorJFShermanCAWilloughbyKet al
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol
2015; 10: 232–236.25526238
GainorJFShermanCAWilloughbyKet al
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol
2015; 10: 232–236.25526238,
GainorJFShermanCAWilloughbyKet al
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol
2015; 10: 232–236.25526238
-
(
CostaDBKobayashiSPandyaSSet al
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol
2011; 29: e443–e445.21422405)
CostaDBKobayashiSPandyaSSet al
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol
2011; 29: e443–e445.21422405
CostaDBKobayashiSPandyaSSet al
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol
2011; 29: e443–e445.21422405,
CostaDBKobayashiSPandyaSSet al
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol
2011; 29: e443–e445.21422405
-
R.
Doebele,
Amanda
Pilling,
D.
Aisner,
T.
Kutateladze,
A.
Le,
A.
Weickhardt,
K.
Kondo,
Derek
Linderman,
L.
Heasley,
W.
Franklin,
M.
Varella-Garcia,
R.
Camidge
(2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Clinical Cancer Research, 18
-
(
SodaMChoiYLEnomotoMet al
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature
2007; 448: 561–566.17625570)
SodaMChoiYLEnomotoMet al
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature
2007; 448: 561–566.17625570
SodaMChoiYLEnomotoMet al
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature
2007; 448: 561–566.17625570,
SodaMChoiYLEnomotoMet al
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature
2007; 448: 561–566.17625570
-
N.
Lindeman,
P.
Cagle,
D.
Aisner,
M.
Arcila,
M.
Beasley,
E.
Bernicker,
Carol
Colasacco,
S.
Dacic,
F.
Hirsch,
K.
Kerr,
D.
Kwiatkowski,
M.
Ladanyi,
J.
Nowak,
L.
Sholl,
Robyn
Temple-Smolkin,
B.
Solomon,
L.
Souter,
E.
Thunnissen,
M.
Tsao,
Christina
Ventura,
M.
Wynes,
Y.
Yatabe
(2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Journal of Thoracic Oncology, 13
-
(2015)
Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ nonsmall-cell lung cancer (NSCLC)
-
(
MullerIBde LangenAJGiovannettiEet al
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther
2017; 10: 4535–4541.28979145)
MullerIBde LangenAJGiovannettiEet al
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther
2017; 10: 4535–4541.28979145
MullerIBde LangenAJGiovannettiEet al
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther
2017; 10: 4535–4541.28979145,
MullerIBde LangenAJGiovannettiEet al
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther
2017; 10: 4535–4541.28979145
-
J.
Gainor,
A.
Chi,
J.
Logan,
R.
Hu,
K.
Oh,
P.
Brastianos,
H.
Shih,
A.
Shaw
(2016)
Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 2
-
(
TamuraTKiuraKSetoTet al
Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol
2017; 35: 1515–1521.28296581)
TamuraTKiuraKSetoTet al
Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol
2017; 35: 1515–1521.28296581
TamuraTKiuraKSetoTet al
Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol
2017; 35: 1515–1521.28296581,
TamuraTKiuraKSetoTet al
Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol
2017; 35: 1515–1521.28296581
-
(
MullerIBDe LangenAJHoneywellRJet al
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther
2016; 16: 147–157.26654422)
MullerIBDe LangenAJHoneywellRJet al
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther
2016; 16: 147–157.26654422
MullerIBDe LangenAJHoneywellRJet al
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther
2016; 16: 147–157.26654422,
MullerIBDe LangenAJHoneywellRJet al
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Rev Anticancer Ther
2016; 16: 147–157.26654422
-
(
KwakELBangYJCamidgeDRet al
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010; 363: 1693–1703.20979469)
KwakELBangYJCamidgeDRet al
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010; 363: 1693–1703.20979469
KwakELBangYJCamidgeDRet al
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010; 363: 1693–1703.20979469,
KwakELBangYJCamidgeDRet al
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010; 363: 1693–1703.20979469
-
(
SiegelRLMillerKDJemalA.
Cancer statistics, 2017. CA Cancer J Clin
2017; 67: 7–30.28055103)
SiegelRLMillerKDJemalA.
Cancer statistics, 2017. CA Cancer J Clin
2017; 67: 7–30.28055103
SiegelRLMillerKDJemalA.
Cancer statistics, 2017. CA Cancer J Clin
2017; 67: 7–30.28055103,
SiegelRLMillerKDJemalA.
Cancer statistics, 2017. CA Cancer J Clin
2017; 67: 7–30.28055103
-
J.
Boland,
J.
Jang,
Jun
Li,
Ping
Yang,
J.
Jen,
E.
Yi
(2012)
MET And EGFR Mutations Identified In ALK Rearranged Pulmonary Adenocarcinoma: Molecular Analysis Of 25 ALK-Positive Cases
-
B.
Solomon,
T.
Mok,
Dong-Wan
Kim,
Yi-long
Wu,
K.
Nakagawa,
T.
Mekhail,
E.
Felip,
F.
Cappuzzo,
J.
Paolini,
T.
Usari,
S.
Iyer,
A.
Reisman,
K.
Wilner,
J.
Tursi,
F.
Blackhall
(2014)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
The New England journal of medicine, 371 23
-
S.
Peters,
D.
Camidge,
A.
Shaw,
S.
Gadgeel,
J.
Ahn,
Dong-Wan
Kim,
S.
Ou,
M.
Pérol,
R.
Dziadziuszko,
R.
Rosell,
A.
Zeaiter,
E.
Mitry,
S.
Golding,
B.
Balas,
J.
Noé,
P.
Morcos,
T.
Mok
(2017)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 377
-
M.
Awad,
Ryohei
Katayama,
M.
McTigue,
Wei
Liu,
Ya-Li
Deng,
A.
Brooun,
L.
Friboulet,
Donghui
Huang,
M.
Falk,
Sergei
Timofeevski,
K.
Wilner,
Elizabeth
Lockerman,
Tahsin
Khan,
Sidra
Mahmood,
J.
Gainor,
S.
Digumarthy,
James
Stone,
M.
Mino‐Kenudson,
J.
Christensen,
A.
Iafrate,
J.
Engelman,
A.
Shaw
(2013)
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
The New England journal of medicine, 368 25
-
(
LinJJRielyGJShawAT.
Targeting ALK: precision medicine takes on drug resistance. Cancer Discov
2017; 7: 137–155.28122866)
LinJJRielyGJShawAT.
Targeting ALK: precision medicine takes on drug resistance. Cancer Discov
2017; 7: 137–155.28122866
LinJJRielyGJShawAT.
Targeting ALK: precision medicine takes on drug resistance. Cancer Discov
2017; 7: 137–155.28122866,
LinJJRielyGJShawAT.
Targeting ALK: precision medicine takes on drug resistance. Cancer Discov
2017; 7: 137–155.28122866
-
V.
Zhu,
S.
Ou
(2017)
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
Expert Opinion on Drug Safety, 16
-
(
YoshidaTOyaYTanakaKet al
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer. J Clin Oncol
2016; 34: 3383–3389.27354483)
YoshidaTOyaYTanakaKet al
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer. J Clin Oncol
2016; 34: 3383–3389.27354483
YoshidaTOyaYTanakaKet al
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer. J Clin Oncol
2016; 34: 3383–3389.27354483,
YoshidaTOyaYTanakaKet al
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer. J Clin Oncol
2016; 34: 3383–3389.27354483
-
I.
Muller,
A.
Langen,
E.
Giovannetti,
G.
Peters
(2017)
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
OncoTargets and therapy, 10
-
(
SoriaJCTanDSWChiariRet al
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet
2017;389: 917–929.28126333)
SoriaJCTanDSWChiariRet al
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet
2017;389: 917–929.28126333
SoriaJCTanDSWChiariRet al
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet
2017;389: 917–929.28126333,
SoriaJCTanDSWChiariRet al
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet
2017;389: 917–929.28126333
-
D.
Galetta,
A.
Rossi,
S.
Pisconti,
G.
Colucci
(2012)
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
Expert Opinion on Therapeutic Targets, 16
-
J.
Gainor,
L.
Dardaei,
S.
Yoda,
L.
Friboulet,
I.
Leshchiner,
Ryohei
Katayama,
I.
Dagogo-Jack,
S.
Gadgeel,
Katherine
Schultz,
Manrose
Singh,
E.
Chin,
Melissa
Parks,
Dana
Lee,
R.
Dicecca,
Elizabeth
Lockerman,
T.
Huynh,
J.
Logan,
Lauren
Ritterhouse,
Long
Le,
A.
Muniappan,
S.
Digumarthy,
C.
Channick,
C.
Keyes,
G.
Getz,
D.
Dias-Santagata,
R.
Heist,
J.
Lennerz,
L.
Sequist,
C.
Benes,
A.
Iafrate,
M.
Mino‐Kenudson,
J.
Engelman,
A.
Shaw
(2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Cancer Discovery, 6
-
P.
Hofman
(2017)
ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
Cancers, 9
-
(
MokTSKPetersSCamidgeDRet al
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol
2017; 28(Suppl. 10): x186–x195.)
MokTSKPetersSCamidgeDRet al
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol
2017; 28(Suppl. 10): x186–x195.
MokTSKPetersSCamidgeDRet al
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol
2017; 28(Suppl. 10): x186–x195.,
MokTSKPetersSCamidgeDRet al
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study. Ann Oncol
2017; 28(Suppl. 10): x186–x195.
-
(
OuSHIAhnJSDe PetrisL
Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol
2016; 34: 661–668.26598747)
OuSHIAhnJSDe PetrisL
Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol
2016; 34: 661–668.26598747
OuSHIAhnJSDe PetrisL
Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol
2016; 34: 661–668.26598747,
OuSHIAhnJSDe PetrisL
Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol
2016; 34: 661–668.26598747
-
B.
Hallberg,
R.
Palmer
(2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Nature Reviews Cancer, 13
-
(
MorcosPNNueeschEJaminionFet al
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. Epub ahead of print 10 May 2018. DOI: 10.1007/s00280-018-3597-5.)
MorcosPNNueeschEJaminionFet al
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. Epub ahead of print 10 May 2018. DOI: 10.1007/s00280-018-3597-5.
MorcosPNNueeschEJaminionFet al
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. Epub ahead of print 10 May 2018. DOI: 10.1007/s00280-018-3597-5.,
MorcosPNNueeschEJaminionFet al
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. Epub ahead of print 10 May 2018. DOI: 10.1007/s00280-018-3597-5.
-
T.
Kim,
Y.
Park,
K.
Muro,
R.
Xu,
S.
Han,
K.
Yamazaki,
Wei
Wang,
J.
Ahn,
H.
Uetake,
Y.
Deng,
S.
Cho,
H.
Matsumoto,
Y.
Ba,
K.
Lee,
T.
Nishina,
Zhang
Tao,
S.
Iwasa,
S.
Morita,
J.
Sakamoto
(2017)
LBA3_PRRandomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)
Annals of Oncology, 28
-
(
TranPNKlempnerSJ.
Focus on alectinib and competitor compounds for second-line therapy in ALK-rearranged NSCLC. Front Med (Lausanne)
2016; 3: 65.27965961)
TranPNKlempnerSJ.
Focus on alectinib and competitor compounds for second-line therapy in ALK-rearranged NSCLC. Front Med (Lausanne)
2016; 3: 65.27965961
TranPNKlempnerSJ.
Focus on alectinib and competitor compounds for second-line therapy in ALK-rearranged NSCLC. Front Med (Lausanne)
2016; 3: 65.27965961,
TranPNKlempnerSJ.
Focus on alectinib and competitor compounds for second-line therapy in ALK-rearranged NSCLC. Front Med (Lausanne)
2016; 3: 65.27965961
-
F.
Barlesi,
A.
Dingemans,
I.
Ou,
J.
Ahn,
L.
Petris,
Dong-Wan
Kim,
J.
Yang,
B.
Hughes,
H.
Léna,
D.
Moro-Sibilot,
A.
Bearz,
S.
Viteri,
T.
Mekhail,
A.
Spira,
A.
Zeaiter,
W.
Bordogna,
C.
Sturm,
S.
Golding,
P.
Morcos,
R.
Govindan
(2015)
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)
European Journal of Cancer, 51
-
C.
Woo,
S.
Seo,
S.
Kim,
S.
Jang,
K.
Park,
J.
Song,
B.
Lee,
Mark
Richards,
Richard
Bayliss,
D.
Lee,
J.
Choi
(2016)
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
Annals of Oncology, 28
-
(
DoebeleRCPillingABAisnerDLet al
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non small cell lung cancer. Clin Cancer Res
2012; 18: 1472–1482.22235099)
DoebeleRCPillingABAisnerDLet al
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non small cell lung cancer. Clin Cancer Res
2012; 18: 1472–1482.22235099
DoebeleRCPillingABAisnerDLet al
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non small cell lung cancer. Clin Cancer Res
2012; 18: 1472–1482.22235099,
DoebeleRCPillingABAisnerDLet al
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non small cell lung cancer. Clin Cancer Res
2012; 18: 1472–1482.22235099
-
(2009)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4ALK
-
(
ALECENSA: alectinib hydrochloride capsule, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb (accessed 25 January 2018).)
ALECENSA: alectinib hydrochloride capsule, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb (accessed 25 January 2018).
ALECENSA: alectinib hydrochloride capsule, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb (accessed 25 January 2018).,
ALECENSA: alectinib hydrochloride capsule, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb (accessed 25 January 2018).
-
(
SasakiTRodigSJChirieacLRet al
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer
2010; 46: 1773–1780.20418096)
SasakiTRodigSJChirieacLRet al
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer
2010; 46: 1773–1780.20418096
SasakiTRodigSJChirieacLRet al
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer
2010; 46: 1773–1780.20418096,
SasakiTRodigSJChirieacLRet al
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer
2010; 46: 1773–1780.20418096
-
S.
Ou,
L.
Gandhi,
S.
Gadgeel,
F.
Barlesi,
J.
Yang,
L.
Petris,
Dong-Wan
Kim,
R.
Govindan,
A.
Dingemans,
L.
Crinò,
Lena
Herve,
S.
Popat,
J.
Ahn,
É.
Dansin,
A.
Zeaiter,
B.
Müller,
H.
Johannsdottir,
B.
Balas,
P.
Morcos,
A.
Shaw
(2018)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology, 36
-
T.
Seto,
K.
Kiura,
M.
Nishio,
K.
Nakagawa,
M.
Maemondo,
A.
Inoue,
T.
Hida,
N.
Yamamoto,
H.
Yoshioka,
M.
Harada,
Y.
Ohe,
N.
Nogami,
K.
Takeuchi,
T.
Shimada,
Tomohiro
Tanaka,
T.
Tamura
(2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
The Lancet. Oncology, 14 7
-
(
SolomonBJMokTKimDWet al
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med
2014; 371: 2167–2177.25470694)
SolomonBJMokTKimDWet al
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med
2014; 371: 2167–2177.25470694
SolomonBJMokTKimDWet al
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med
2014; 371: 2167–2177.25470694,
SolomonBJMokTKimDWet al
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med
2014; 371: 2167–2177.25470694
-
J.
Gainor,
C.
Sherman,
K.
Willoughby,
J.
Logan,
E.
Kennedy,
P.
Brastianos,
A.
Chi,
A.
Shaw
(2015)
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Journal of Thoracic Oncology, 10
-
(
GadgeelSMGandhiLRielyGJet al
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol
2014; 15: 1119–1128.25153538)
GadgeelSMGandhiLRielyGJet al
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol
2014; 15: 1119–1128.25153538
GadgeelSMGandhiLRielyGJet al
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol
2014; 15: 1119–1128.25153538,
GadgeelSMGandhiLRielyGJet al
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol
2014; 15: 1119–1128.25153538
-
T.
Yoshida,
Y.
Oya,
Kosuke
Tanaka,
J.
Shimizu,
Y.
Horio,
H.
Kuroda,
Y.
Sakao,
T.
Hida,
Y.
Yatabe
(2016)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 28
-
(2009)
KIF5BALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK positive lung cancer
-
FDA D.I.S.C.O.: two approvals for ALK-positive non-small cell lung cancer
-
(
ShawATGandhiLGadgeelSet al
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol
2016; 17: 234–242.26708155)
ShawATGandhiLGadgeelSet al
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol
2016; 17: 234–242.26708155
ShawATGandhiLGadgeelSet al
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol
2016; 17: 234–242.26708155,
ShawATGandhiLGadgeelSet al
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol
2016; 17: 234–242.26708155
-
(
ZhuVOuSH.
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf
2017; 16: 509–514.28276856)
ZhuVOuSH.
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf
2017; 16: 509–514.28276856
ZhuVOuSH.
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf
2017; 16: 509–514.28276856,
ZhuVOuSH.
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf
2017; 16: 509–514.28276856
-
(
MorrisSWKirsteinMNValentineMBet al
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science
1994; 263: 1281–1284.8122112)
MorrisSWKirsteinMNValentineMBet al
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science
1994; 263: 1281–1284.8122112
MorrisSWKirsteinMNValentineMBet al
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science
1994; 263: 1281–1284.8122112,
MorrisSWKirsteinMNValentineMBet al
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science
1994; 263: 1281–1284.8122112
-
(
CostaDBShawATOuSHet al
Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol
2015; 33: 1881–1888.25624436)
CostaDBShawATOuSHet al
Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol
2015; 33: 1881–1888.25624436
CostaDBShawATOuSHet al
Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol
2015; 33: 1881–1888.25624436,
CostaDBShawATOuSHet al
Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol
2015; 33: 1881–1888.25624436
-
(
SabirSRYeohSJacksonGet al
EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers
2017; 9: 1–9.)
SabirSRYeohSJacksonGet al
EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers
2017; 9: 1–9.
SabirSRYeohSJacksonGet al
EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers
2017; 9: 1–9.,
SabirSRYeohSJacksonGet al
EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers
2017; 9: 1–9.
-
A.
Rossi
(2016)
Alectinib for ALK-positive non-small-cell lung cancer
Expert Review of Clinical Pharmacology, 9
-
S.
Ou,
J.
Ahn,
L.
Petris,
R.
Govindan,
J.
Yang,
B.
Hughes,
H.
Léna,
D.
Moro-Sibilot,
A.
Bearz,
Santiago
Ramírez,
T.
Mekhail,
A.
Spira,
W.
Bordogna,
B.
Balas,
P.
Morcos,
Annabelle
Monnet,
A.
Zeaiter,
Dong-Wan
Kim
(2016)
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 7
-
S.
Morris,
M.
Kirstein,
M.
Valentine,
K.
Dittmer,
D.
Shapiro,
D.
Saltman,
A.
Look
(1994)
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Science, 267 5196
-
T.
Hida,
H.
Nokihara,
M.
Kondo,
Y.
Kim,
K.
Azuma,
T.
Seto,
Y.
Takiguchi,
M.
Nishio,
H.
Yoshioka,
F.
Imamura,
K.
Hotta,
Satoshi
Watanabe,
K.
Goto,
M.
Satouchi,
T.
Kozuki,
T.
Shukuya,
K.
Nakagawa,
T.
Mitsudomi,
N.
Yamamoto,
T.
Asakawa,
Ryoichi
Asabe,
Tomohiro
Tanaka,
T.
Tamura
(2017)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
The Lancet, 390
-
D.
Camidge,
S.
Gadgeel,
S.
Ou,
L.
Gandhi,
Gregory
Riely,
J.
Cetnar,
H.
West,
M.
Socinski,
A.
Chiappori,
T.
Mekhail,
B.
Chao,
H.
Borghaei,
K.
Gold,
W.
Bordogna,
B.
Balas,
J.
Noé,
S.
Golding,
A.
Zeaiter,
A.
Shaw
(2017)
MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology, 12
-
D.
Costa,
Susumu
Kobayashi,
S.
Pandya,
W.
Yeo,
Zhongzhou
Shen,
Weiwei
Tan,
K.
Wilner
(2011)
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15
-
(
BolandJMJangJSLiJet al
MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol
2013; 8: 574–581.23449277)
BolandJMJangJSLiJet al
MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol
2013; 8: 574–581.23449277
BolandJMJangJSLiJet al
MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol
2013; 8: 574–581.23449277,
BolandJMJangJSLiJet al
MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol
2013; 8: 574–581.23449277
-
S.
Gadgeel,
A.
Shaw,
F.
Barlesi,
L.
Crinò,
J.
Yang,
A.
Dingemans,
Dong-Wan
Kim,
F.
Marinis,
M.
Schulz,
Shiyao
Liu,
Ravindra
Gupta,
A.
Kotb,
S.
Ou
(2017)
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
British Journal of Cancer, 118
-
M.
Soda,
Y.
Choi,
M.
Enomoto,
S.
Takada,
Y.
Yamashita,
S.
Ishikawa,
Shin-ichiro
Fujiwara,
Hideki
Watanabe,
K.
Kurashina,
H.
Hatanaka,
M.
Bando,
S.
Ohno,
Y.
Ishikawa,
H.
Aburatani,
T.
Niki,
Y.
Sohara,
Y.
Sugiyama,
H.
Mano
(2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Nature, 448
-
(
RossiA.
Alectinib for ALK-positive non-small-cell lung cancer. Exp Rev Clin Pharmacol
2016; 9: 1005–1013.)
RossiA.
Alectinib for ALK-positive non-small-cell lung cancer. Exp Rev Clin Pharmacol
2016; 9: 1005–1013.
RossiA.
Alectinib for ALK-positive non-small-cell lung cancer. Exp Rev Clin Pharmacol
2016; 9: 1005–1013.,
RossiA.
Alectinib for ALK-positive non-small-cell lung cancer. Exp Rev Clin Pharmacol
2016; 9: 1005–1013.
-
A.
Shaw,
L.
Gandhi,
S.
Gadgeel,
Gregory
Riely,
J.
Cetnar,
H.
West,
D.
Camidge,
M.
Socinski,
A.
Chiappori,
T.
Mekhail,
B.
Chao,
H.
Borghaei,
K.
Gold,
A.
Zeaiter,
W.
Bordogna,
B.
Balas,
O.
Puig,
V.
Henschel,
S.
Ou
(2016)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
The Lancet. Oncology, 17 2
-
F.
Casaluce,
A.
Sgambato,
P.
Sacco,
G.
Palazzolo,
P.
Maione,
A.
Rossi,
F.
Ciardiello,
C.
Gridelli
(2016)
Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Current clinical pharmacology, 11 2
-
(
WHO Statistics. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed 21 December 2017).)
WHO Statistics. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed 21 December 2017).
WHO Statistics. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed 21 December 2017).,
WHO Statistics. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed 21 December 2017).
-
R.
Ferré,
M.
Paré,
Lisa
Smith,
M.
Thériault,
A.
Aldis,
E.
Kao,
B.
Mesurolle
(2016)
Retroareolar Carcinomas in Breast Ultrasound: Pearls and Pitfalls
Cancers, 9
-
(
HernandezLPinyolMHernandezSet al
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood
1999; 94: 3265–3268.10556217)
HernandezLPinyolMHernandezSet al
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood
1999; 94: 3265–3268.10556217
HernandezLPinyolMHernandezSet al
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood
1999; 94: 3265–3268.10556217,
HernandezLPinyolMHernandezSet al
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood
1999; 94: 3265–3268.10556217
-
(
TogashiYSodaMSakataSet al
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One
2012; 7: e31323.22347464)
TogashiYSodaMSakataSet al
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One
2012; 7: e31323.22347464
TogashiYSodaMSakataSet al
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One
2012; 7: e31323.22347464,
TogashiYSodaMSakataSet al
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One
2012; 7: e31323.22347464
-
(
GadgeelSMShawATBarlesiFet al
Cumulative incidence rates for CNS andnon-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
Br J Cancer
2018; 118: 38–42.29149104)
GadgeelSMShawATBarlesiFet al
Cumulative incidence rates for CNS andnon-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
Br J Cancer
2018; 118: 38–42.29149104
GadgeelSMShawATBarlesiFet al
Cumulative incidence rates for CNS andnon-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
Br J Cancer
2018; 118: 38–42.29149104,
GadgeelSMShawATBarlesiFet al
Cumulative incidence rates for CNS andnon-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
Br J Cancer
2018; 118: 38–42.29149104
-
T.
Tamura,
K.
Kiura,
T.
Seto,
K.
Nakagawa,
M.
Maemondo,
A.
Inoue,
T.
Hida,
H.
Yoshioka,
M.
Harada,
Y.
Ohe,
N.
Nogami,
H.
Murakami,
H.
Kuriki,
T.
Shimada,
Tomohiro
Tanaka,
K.
Takeuchi,
M.
Nishio
(2017)
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
Journal of Clinical Oncology, 35
-
S.
Gadgeel,
L.
Gandhi,
Gregory
Riely,
A.
Chiappori,
H.
West,
Michele
Azada,
P.
Morcos,
Ruey-min
Lee,
L.
Garcia,
Li
Yu,
F.
Boisserie,
L.
Laurenzio,
S.
Golding,
Jotaro
Sato,
S.
Yokoyama,
Tomohiro
Tanaka,
S.
Ou
(2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
The Lancet. Oncology, 15 10
-
Klarisa
Rikova,
A.
Guo,
Q.
Zeng,
A.
Possemato,
Jian
Yu,
H.
Haack,
J.
Nardone,
Kimberly
Lee,
C.
Reeves,
Y.
Li,
Ye-rong
Hu,
Zhiping
Tan,
M.
Stokes,
Laura
Sullivan,
Jeffrey
Mitchell,
Randy
Wetzel,
J.
Macneill,
J.
Ren,
Jin
Yuan,
C.
Bakalarski,
J.
Villén,
J.
Kornhauser,
Bradley
Smith,
Dai-qiang
Li,
Xinmin
Zhou,
S.
Gygi,
T.
Gu,
R.
Polakiewicz,
J.
Rush,
M.
Comb
(2007)
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Cell, 131
-
K.
Takeuchi,
Y.
Choi,
Yuki
Togashi,
M.
Soda,
S.
Hatano,
K.
Inamura,
S.
Takada,
Toshihide
Ueno,
Y.
Yamashita,
Y.
Satoh,
S.
Okumura,
K.
Nakagawa,
Y.
Ishikawa,
H.
Mano
(2009)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Clinical Cancer Research, 15
-
(
WooCGSeoSKimSWet al
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol
2017; 28: 791–797.28039177)
WooCGSeoSKimSWet al
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol
2017; 28: 791–797.28039177
WooCGSeoSKimSWet al
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol
2017; 28: 791–797.28039177,
WooCGSeoSKimSWet al
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol
2017; 28: 791–797.28039177
-
(
LindemanNICaglePTAisnerDLet al
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol
2018; 13: 323–358.29396253)
LindemanNICaglePTAisnerDLet al
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol
2018; 13: 323–358.29396253
LindemanNICaglePTAisnerDLet al
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol
2018; 13: 323–358.29396253,
LindemanNICaglePTAisnerDLet al
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol
2018; 13: 323–358.29396253
-
Tatsushi
Kodama,
M.
Hasegawa,
Kenji
Takanashi,
Yuji
Sakurai,
O.
Kondoh,
H.
Sakamoto
(2014)
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Cancer Chemotherapy and Pharmacology, 74
-
S.
Gadgeel,
A.
Shaw,
R.
Govindan,
L.
Gandhi,
M.
Socinski,
D.
Camidge,
L.
Petris,
Dong-Wan
Kim,
A.
Chiappori,
D.
Moro-Sibilot,
M.
Duruisseaux,
L.
Crinò,
T.
Pas,
É.
Dansin,
A.
Tessmer,
J.
Yang,
Ji-Youn
Han,
W.
Bordogna,
S.
Golding,
A.
Zeaiter,
S.
Ou
(2016)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 34
-
P.
Morcos,
E.
Nueesch,
Félix
Jaminion,
E.
Guerini,
J.
Hsu,
W.
Bordogna,
B.
Balas,
F.
Mercier
(2018)
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Cancer Chemotherapy and Pharmacology, 82
-
(
SolomonBVarella-GarciaMCamidgeDR.
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol
2009; 4: 1450–1454.20009909)
SolomonBVarella-GarciaMCamidgeDR.
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol
2009; 4: 1450–1454.20009909
SolomonBVarella-GarciaMCamidgeDR.
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol
2009; 4: 1450–1454.20009909,
SolomonBVarella-GarciaMCamidgeDR.
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol
2009; 4: 1450–1454.20009909
-
(
HidaTNokiharaHKondoMet al
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet
2017; 390(10089): 29–39.28501140)
HidaTNokiharaHKondoMet al
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet
2017; 390(10089): 29–39.28501140
HidaTNokiharaHKondoMet al
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet
2017; 390(10089): 29–39.28501140,
HidaTNokiharaHKondoMet al
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet
2017; 390(10089): 29–39.28501140
-
J.
Soria,
D.
Tan,
R.
Chiari,
Yi-long
Wu,
L.
Paz-Ares,
J.
Wolf,
Sarayut
Geater,
S.
Orlov,
D.
Cortinovis,
Chong-Jen
Yu,
M.
Hochmair,
A.
Cortot,
C.
Tsai,
D.
Moro-Sibilot,
R.
Campelo,
T.
McCulloch,
P.
Sen,
M.
Dugan,
Serafino
Pantano,
F.
Branle,
C.
Massacesi,
G.
Castro
(2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
The Lancet, 389
-
(
HamiltonGRathBBurghuberO.
Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol
2015; 11: 835–842.25732197)
HamiltonGRathBBurghuberO.
Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol
2015; 11: 835–842.25732197
HamiltonGRathBBurghuberO.
Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol
2015; 11: 835–842.25732197,
HamiltonGRathBBurghuberO.
Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol
2015; 11: 835–842.25732197
-
(
BarlesiFDingemansAMCOuIet al
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer
2015; 51(Suppl. 3): S635.)
BarlesiFDingemansAMCOuIet al
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer
2015; 51(Suppl. 3): S635.
BarlesiFDingemansAMCOuIet al
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer
2015; 51(Suppl. 3): S635.,
BarlesiFDingemansAMCOuIet al
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer
2015; 51(Suppl. 3): S635.
-
T.
Mok,
S.
Peters,
D.
Camidge,
S.
Ou,
J.
Ahn,
E.
Tan,
Zhi
Li,
J-O.
Lee,
B.
Cho,
Sarayut
Geater,
Sriuranpong,
J.
Ho,
O.
Chan,
A.
Zeaiter,
B.
Balas,
E.
Nueesch,
E.
Mitry,
P.
Morcos,
D-W.
Kim
(2017)
410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
Annals of Oncology, 28
-
(2017)
02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive nonsmall-cell lung cancer
-
B.
Solomon,
Marileila
Varella-Garcia,
D.
Camidge
(2009)
ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Journal of Thoracic Oncology, 4
-
(
OuSHIGandhiLGadgeelSMet al
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol
2018; 36(Suppl.): abstract 9072.)
OuSHIGandhiLGadgeelSMet al
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol
2018; 36(Suppl.): abstract 9072.
OuSHIGandhiLGadgeelSMet al
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol
2018; 36(Suppl.): abstract 9072.,
OuSHIGandhiLGadgeelSMet al
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol
2018; 36(Suppl.): abstract 9072.
-
(
AwadMMKatayamaRMcTigueMet al
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med
2013; 368: 2395–2401.23724914)
AwadMMKatayamaRMcTigueMet al
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med
2013; 368: 2395–2401.23724914
AwadMMKatayamaRMcTigueMet al
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med
2013; 368: 2395–2401.23724914,
AwadMMKatayamaRMcTigueMet al
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med
2013; 368: 2395–2401.23724914
-
(2017)
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
-
L.
Mezquita,
B.
Besse
(2016)
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.
Journal of thoracic disease, 8 11
-
(
KimYHidaTNokiharaHet al
Alectinib (ALC) versus Crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from phase III study (J-ALEX). J Thoracic Oncol
2017; 12(Suppl.): S378.)
KimYHidaTNokiharaHet al
Alectinib (ALC) versus Crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from phase III study (J-ALEX). J Thoracic Oncol
2017; 12(Suppl.): S378.
KimYHidaTNokiharaHet al
Alectinib (ALC) versus Crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from phase III study (J-ALEX). J Thoracic Oncol
2017; 12(Suppl.): S378.,
KimYHidaTNokiharaHet al
Alectinib (ALC) versus Crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from phase III study (J-ALEX). J Thoracic Oncol
2017; 12(Suppl.): S378.
-
P.
Tran,
S.
Klempner
(2016)
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
Frontiers in Medicine, 3
-
(
HofmanP.
ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers
2017; 9: 1–16.)
HofmanP.
ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers
2017; 9: 1–16.
HofmanP.
ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers
2017; 9: 1–16.,
HofmanP.
ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers
2017; 9: 1–16.
-
E.
Kwak,
Y.
Bang,
D.
Camidge,
A.
Shaw,
B.
Solomon,
Robert
Maki,
Sai-Hong
Ou,
Bruce
Dezube,
P.
Jänne,
Daniel,
B.
Costa,
M.
Varella-Garcia,
W.
Kim,
Thomas
Lynch,
P.
Fidias,
Hannah
Stubbs,
J.
Engelman,
V.
Lecia,
Sequist,
Weiwei
Tan,
L.
Gandhi,
M.
Mino‐Kenudson,
Greg
Wei,
S.
Shreeve,
M.
Ratain,
Jeffrey,
Settleman,
James
Christensen,
D.
Haber,
K.
Wilner,
R.
Salgia,
Geoffrey
Shapiro,
J.
Clark,
A.
Iafrate
(2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
The New England journal of medicine, 363 18
-
(
XALKORI [Package Insert]. New York, NY: Pfizer, Inc, 2011.)
XALKORI [Package Insert]. New York, NY: Pfizer, Inc, 2011.
XALKORI [Package Insert]. New York, NY: Pfizer, Inc, 2011.,
XALKORI [Package Insert]. New York, NY: Pfizer, Inc, 2011.
-
D.
Costa,
A.
Shaw,
S.
Ou,
B.
Solomon,
Gregory
Riely,
M.
Ahn,
Caicun
Zhou,
S.
Shreeve,
P.
Selaru,
A.
Polli,
P.
Schnell,
K.
Wilner,
R.
Wiltshire,
D.
Camidge,
L.
Crinò
(2015)
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
-
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer